JY 207
Alternative Names: JY-207Latest Information Update: 24 Jun 2024
At a glance
- Originator Shenzhen Enduring Biotech
 - Class Antineoplastics; Drug conjugates; Immunoconjugates; Immunoglobulin Fv fragments; Immunotherapies; Polyethylene glycols; Recombinant fusion proteins
 - Mechanism of Action Antibody-dependent cell cytotoxicity; CD47 antigen inhibitors; Cell death stimulants; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
 
- 
          
            
              Orphan Drug Status
              No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 - New Molecular Entity Yes
 
Highest Development Phases
- Preclinical Solid tumours
 
Most Recent Events
- 05 Apr 2024 Pharmacodynamics data from a preclinical studies in Solid tumors presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
 - 14 Apr 2023 Pharmacodynamics, pharmacokinetics and safety data from preclinical studies in Solid tumors presented at the American Association for Cancer Research (AACR-2023)
 - 25 Nov 2022 3733258;3733225: Patent info added.